Human papillomavirus (HPV)
Each year cervical cancer kills 275,000 women worldwide, mostly in developing countries. There are two vaccines against the major cancer causing strains of human papillomavirus (HPV), the infectious cause of cervical cancer. When given to girls prior to sexual debut, the vaccines are more than 92 percent effective in preventing persistent HPV infection and 100 percent effective in preventing vaccine type-specific cervical lesions (precancer). For women already infected with persistent HPV, when cervical precancer is detected early, treatment success rates are high.
Comprehensive Cervical Cancer Prevention and Control: A Healthier Future for Girls and Women (2013)
A World Health Organization Guidance Note that advocates for a comprehensive approach to cervical cancer prevention and control, including HPV vaccination.
HPV Vaccine Training Materials for Countries Introducing Gardasil (or Silgard)™ 1 Dose Vaccine (2013)
Training modules on key aspects of the introduction of the HPV vaccine Gardasil (or Silgard)™.
Featured PATH resources
Cervical Cancer Prevention at PATH: Two Decades of Progress Toward a World Free of HPV-Related Cancers (2013)
A report that describes PATH's key cervical cancer prevention initiatives, including support to HPV vaccine programs.
Cervical Cancer Screening and Treatment in Low-Resource Settings: Practical Experience From PATH (2013)
A report that examines screening and treatment of adult women for precancerous lesions as part of PATH's HPV vaccination demonstration projects.
Page last updated: October 2013.